| | | EXHIBIT 99.02 |
| | | |
| | Hampshire International Business Park
Chineham Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com |  |
| | | |
| | Press Release | |
| | | |
28 February 2007
Shire plc (the "Company")
The Company announces that on 27 February 2007 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire plc Portfolio Share Plan (the “Plan”).
Awards of Stock Settled Appreciation Rights (“SARs”) under Part A of the Plan
| Name of PDMR | Type of Security | No of Ordinary
Shares or ADRs | Exercise
price |
Matthew Emmens (Executive
Director)* | American Depositary
Receipt (“ADR”) | 93,840 | $64.10 |
Angus Russell (Executive
Director)* | Ordinary Share | 117,495 | £10.99 |
| Michael Cola | ADR | 19,334 | $64.10 |
| David Pendergast | ADR | 17,667 | $64.10 |
| Tatjana May | Ordinary Share | 40,000 | £10.99 |
| Barbara Deptula | ADR | 11,667 | $64.10 |
| Eliseo Salinas | ADR | 10,667 | $64.10 |
| Joseph Rus | ADR | 11,334 | $64.10 |
| Anita Graham | ADR | 10,000 | $64.10 |
| Caroline West | ADR | 15,000 | $64.10 |
*Awards to Executive Directors are subject to performance targetsSARs will normally vest after three years, subject to any performance targets. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.
Performance Share Awards (“PSP Awards”) under Part B of the Plan
| Name of PDMR | Type of Security | No of Ordinary
Shares or ADRs | Market
value |
Matthew Emmens (Executive
Director)* | American Depositary
Receipt (“ADR”) | 70,380 | $64.10 |
Angus Russell (Executive
Director)* | Ordinary Share | 80,000 | £10.99 |
| Michael Cola | ADR | 14,000 | $64.10 |
| David Pendergast | ADR | 13,000 | $64.10 |
| Tatjana May | Ordinary Share | 30,000 | £10.99 |
| Barbara Deptula | ADR | 10,000 | $64.10 |
| Eliseo Salinas | ADR | 8,334 | $64.10 |
| Joseph Rus | ADR | 8,334 | $64.10 |
Registered in England 2883758 Registered Office as above
| Anita Graham | ADR | 8,334 | $64.10 |
*Awards to Executive Directors are subject to performance targetsThe PSP awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADRs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of PSP awards.
T May
Company Secretary
For further information please contact:
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| | Eric Rojas (North America) | +1 484 595 8252 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website:www.shire.com.
Registered in England 2883758 Registered Office as above
